-
Innovation Ranking
NewInnovation Ranking – Sio Gene Therapies Inc
Sio Gene Therapies Inc (Sio Gene) is a clinical-stage biopharmaceutical company that develops and commercializes novel medicines. The company develops medicines for the treatment of multiple forms of dementia and related neurological disorders. Sio Gene's pipeline products comprise AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2. The company’s AXO-Lenti-PD is a lentiviral gene therapy that contains three genes that encode the critical enzymes required for endogenous dopamine synthesis. It develops gene therapies for GM1 and GM2 gangliosidosis including Tay-Sachs disease and Sandhoff disease. The...
-
Innovation Ranking
NewInnovation Ranking – Daan Gene Co Ltd
Daan Gene Co Ltd (Daan Gene) is a provider of molecular diagnostic solutions. The company develops and produces in-vitro diagnostic products. It offers products such as real-time PCR products, gene sequencing machines, real-time PCR instruments, nucleic acid extraction instruments, reverse dot blot products, fish products, immunoassay products and rapid test products. Daan Gene’s products also include food safety products, blood collection tubes, and reference material and control material. It also offers biotechnology transfer services and biotechnology consulting and exchange services....
-
Track & Monitor
NewCell & gene therapy in pharma: corneal endothelial cell culturing
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s corneal endothelial cell culturing segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Sector Analysis
NewCell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Product Insights
NewNet Present Value Model: Taysha Gene Therapies Inc’s TSHA-102
Empower your strategies with our Net Present Value Model: Taysha Gene Therapies Inc's TSHA-102 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
NewCell and Gene Therapies in Hemophilia A and B – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies (CGT) in Hemophilia A and B Market Report Overview The hemophilia A and B CGT market reached $12 million in 2023 with massive expansions across therapeutic areas. The CGT in Hemophilia A and B market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in Hemophilia A & B including launch date projections, key clinical trial analysis, analyst consensus forecasts, likelihood of approval analysis, and commentary on current and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy 2 For Oncology in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy 2 For Oncology in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy 2 For Oncology in Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy 2 For Oncology in Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy 2 For Oncology in Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy 2 For Oncology in Leukemia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target GD2 For Oncology in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target GD2 For Oncology in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target GD2 For Oncology...